First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer Preventive use of naldemedine ...

KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential ...

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human ...

The purpose of these two identical studies is to assess the efficacy, safety, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active moderate to severe ...

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safetyPhase 2 clinical trial initiation anticipated ...

Interferon-α nasal spray was safe and effective in reducing COVID-19 risk by 40% in patients with cancer, demonstrating its potential as an additional preventive strategy alongside vaccines and ...

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays ...

A recent clinical trial found that adjunctive dexmedetomidine didn't significantly improve pain scores or reduce opioid consumption in ICU patients with traumatic rib fractures.

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

Objectives To investigate if daily treatment with glyceryl trinitrate (GTN) ointment, over 24 weeks combined with a 12-week eccentric exercise programme is more effective for chronic mid-portion ...